Cargando…

Octreotide-Resistant Acromegaly: Challenges and Solutions

Acromegaly is a rare and severe disease caused by an increased and autonomous secretion of growth hormone (GH), thus resulting in high circulating levels of insulin-like growth factor 1 (IGF-1). Comorbidities and mortality rate are closely related to the disease duration. However, in most cases achi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Corica, Giuliana, Ceraudo, Marco, Campana, Claudia, Nista, Federica, Cocchiara, Francesco, Boschetti, Mara, Zona, Gianluigi, Criminelli, Diego, Ferone, Diego, Gatto, Federico
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7211320/ https://www.ncbi.nlm.nih.gov/pubmed/32440136 http://dx.doi.org/10.2147/TCRM.S183360

Ejemplares similares

Clinical and Radiological Predictors of Biochemical Response to First-Line Treatment With Somatostatin Receptor Ligands in Acromegaly: A Real-Life Perspective
por: Nista, Federica, et al.
Publicado: (2021)

Acromegaly Management in a Tertiary Referral Center After 1 Year of the Coronavirus 2019 Pandemic: A Double Challenge
por: Gatto, Federico, et al.
Publicado: (2021)

Octreotide and Pasireotide Combination Treatment in Somatotroph Tumor Cells: Predominant Role of SST(2) in Mediating Ligand Effects
por: Amarù, Jessica, et al.
Publicado: (2021)

Trabecular Bone Score as a Reliable Measure of Lumbar Spine Bone Microarchitecture in Acromegalic Patients
por: Nazzari, Elena, et al.
Publicado: (2022)

Modulatory activity of testosterone on growth pattern and IGF-1 levels in vanishing testis syndrome: a case report during 15 years of follow-up
por: Franco, Marta, et al.
Publicado: (2023)

Ipsilateral Nasoseptal Flap Pedicle for Transpterygoid Approach: Technical Note
por: Anania, Pasquale, et al.
Publicado: (2021)

Left Ventricular Mass Reduction by a Low-Sodium Diet in Treated Hypertensive Patients †
por: Musso, Natale, et al.
Publicado: (2020)

THU070 Randomized, Placebo-controlled Phase 3 Trial Protocol Assessing The Efficacy And Safety Of Octreotide Subcutaneous Depot (CAM2029) In Patients With Acromegaly
por: Ferone, Diego, et al.
Publicado: (2023)

"Present and future of immunotherapy in Neuroendocrine Tumors"
por: Albertelli, Manuela, et al.
Publicado: (2021)

GH Replacement in the Elderly: Is It Worth It?
por: Ricci Bitti, Silvia, et al.
Publicado: (2021)

Meta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly
por: Giustina, Andrea, et al.
Publicado: (2012)

Effect of octreotide on endometriosis in acromegaly: Case report with review of literature
por: Singh, Seerat, et al.
Publicado: (2014)

Octreotide use for rescue of vision in a pregnant patient with acromegaly
por: Hannon, Anne Marie, et al.
Publicado: (2019)

Durable biochemical response and safety with oral octreotide capsules in acromegaly
por: Samson, Susan L, et al.
Publicado: (2022)

Oxalate nephropathy induced by octreotide treatment for acromegaly: a case report
por: Gariani, Karim, et al.
Publicado: (2012)

Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study
por: Colao, A., et al.
Publicado: (2014)

Prospect of acromegaly therapy: molecular mechanism of clinical drugs octreotide and paltusotine
por: Zhao, Jie, et al.
Publicado: (2023)

Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly
por: Marques-Pamies, Montserrat, et al.
Publicado: (2023)

An unusual cause of adrenal insufficiency with elevation of 17-hydroxyprogesterone: case report
por: Teti, Claudia, et al.
Publicado: (2023)

Comparison of octreotide LAR and lanreotide autogel as post-operative medical treatment in acromegaly
por: Tutuncu, Yasemin, et al.
Publicado: (2011)

Breakdown of Autonomously Functioning Thyroid Nodule Accompanied by Acromegaly After Octreotide Treatment
por: Nomoto, Hiroshi, et al.
Publicado: (2019)

Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results
por: Labadzhyan, Artak, et al.
Publicado: (2021)

A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long-acting repeatable octreotide) in the primary therapy of patients with acromegaly
por: Mercado, Moises, et al.
Publicado: (2007)

Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide
por: Samson, Susan L, et al.
Publicado: (2020)

Advanced acromegaly: successful disease control for more than 16 years using octreotide LA
por: Elshafie, Omayma, et al.
Publicado: (2020)

Correction to: Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results
por: Labadzhyan, Artak, et al.
Publicado: (2021)

Severe respiratory failure in a patient with COVID-19 and acromegaly: rapid improvement after adding octreotide
por: Luty, Jacob, et al.
Publicado: (2021)

Safety Results From MPOWERED, a Phase 3 Trial of Oral Octreotide Capsules in Adults With Acromegaly
por: Freda, Pamela, et al.
Publicado: (2021)

Efficacy and adverse events of octreotide long-acting release in acromegaly: a real-world retrospective study
por: Zhao, Zhe, et al.
Publicado: (2022)

Improved Acromegaly Patient Satisfaction With Oral Octreotide Capsules Compared With Injectable Somatostatin Receptor Ligands in the MPOWERED Trial
por: Gordon, Murray B, et al.
Publicado: (2021)

THU057 Predictors Of Response To Oral Octreotide Capsules In Patients With Acromegaly In A Large Prospective International Trial
por: Fleseriu, Maria, et al.
Publicado: (2023)

MPOWERED Trial Open-Label Extension: Long-term Efficacy and Safety Data for Oral Octreotide Capsules in Acromegaly
por: Fleseriu, Maria, et al.
Publicado: (2023)

Sodium Intake and Target Organ Damage in Hypertension—An Update about the Role of a Real Villain
por: Nista, Federica, et al.
Publicado: (2020)

Acromegaly at diagnosis in 3173 patients from the Liège Acromegaly Survey (LAS) Database
por: Petrossians, Patrick, et al.
Publicado: (2017)

Impact of Vitamin D Deficiency on Tumor Aggressiveness in Neuroendocrine Neoplasms
por: Albertelli, Manuela, et al.
Publicado: (2023)

Change in quality of life in patients with acromegaly after treatment with octreotide LAR: first application of AcroQoL in Korea
por: Chin, Sang Ouk, et al.
Publicado: (2015)

Lanreotide Autogel 120 mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study
por: Neggers, Sebastian JCMM, et al.
Publicado: (2015)

Economics of Acromegaly Treatment in Brazil: A Budget Impact Analysis of Pituitary Surgery Compared with Long-Term Octreotide LAR
por: Porto, Lara Benigno, et al.
Publicado: (2018)

Addition of Cabergoline to Oral Octreotide Capsules May Improve Biochemical Control in Patients With Acromegaly Who Are Inadequately Controlled With Monotherapy
por: Fleseriu, Maria, et al.
Publicado: (2021)

Biological and Biochemical Basis of the Differential Efficacy of First and Second Generation Somatostatin Receptor Ligands in Neuroendocrine Neoplasms
por: Gatto, Federico, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ebr1cv2pb201jb5l6fkb8stcf2